ProMetic Life Science to Acquire Emergent Biosolutions' Plasma Collection Center in Winnipeg, Canada

ProMetic Life Sciences Inc.

announced today that it has entered into an agreement for the acquisition of Emergent BioSolutions'

plasma collection center located in Winnipeg, Canada. The transaction is subject to customary closing conditions. Emergent's plasma collection center is an FDA and Health Canada licensed plasma collection facility. The plasma collection center is conveniently located in close proximity to the existing Emergent Winnipeg based cGMP manufacturing facility, which was recently announced as providing ProMetic with up to 250,000 liters of annual plasma processing capacity. The plasma collection center will start operating under ProMetic's ownership upon granting of the regulatory licenses, in ProMetic's name, by the requisite regulatory authorities. All existing center employees will then transition to be employed by ProMetic. "This acquisition allows us to begin the integration of key operational components, such as plasma collection capabilities, to our proprietary plasma-derived manufacturing platform," mentioned Mr. Pierre Laurin, President and CEO of ProMetic Life Sciences Inc. "The addition of our own plasma collection center is complementary to our expanding network of US based plasma suppliers," added Mr. Laurin. Commenting on the agreement, Mr. Bruce Pritchard, ProMetic's Chief Operating Officer and Chief Financial Officer mentioned: "The acquisition of Emergent's plasma collection center will provide us with valid regulatory approved processes and established standard operating procedures as well as qualified and experienced employees. Commenting further, he added, "We intend to use this facility as the blueprint for the opening of additional plasma collection centers, as part of our strategy of integrating and de-risking our supply chain."